Skip to main content
Premium Trial:

Request an Annual Quote

Olink Acquires IP from In Situ RCP

NEW YORK (GenomeWeb News) – Olink Bioscience said today that it has acquired a family of patents from the Danish firm In Situ RCP that it plans to use in its nucleic acid amplification and protein analysis applications.

The Uppsala, Sweden-based company said the three patents are related to target primed rolling circle amplification and amplifying circular molecules.

Olink's product line is based on its proximity ligation assay technology, which uses dual recognition of analytes and a DNA amplification reporter system.

"The acquisition of these patents is an important step in the process to further strengthen our already strong position within the field of DNA-based immunoassays, as well as to allow us to expand into novel areas of nucleic acid based analysis based on rolling circle amplification," Mats Gullberg, CTO of Olink, said in a statement.

Financial terms of the agreement were not released.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more